Sickle cell pain: a critical reappraisal
Top Cited Papers
- 1 November 2012
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 120 (18), 3647-3656
- https://doi.org/10.1182/blood-2012-04-383430
Abstract
Sickle cell pain includes 3 types: acute recurrent painful crises, chronic pain syndromes, and neuropathic pain. The acute painful crisis is the hallmark of the disease and the most common cause of hospitalization and treatment in the emergency department. It evolves through 4 phases: prodromal, initial, established, and resolving. Each acute painful episode is associated with inflammation that worsens with recurrent episodes, often culminating in serious complications and organ damage, such as acute chest syndrome, multiorgan failure, and sudden death. Three pathophysiologic events operate in unison during the prodromal phase of the crisis: vaso-occlusion, inflammation, and nociception. Aborting the acute painful episode at the prodromal phase could potentially prevent or minimize tissue damage. Our hypothesis is that managing these events with hydration, anti-inflammatory drugs, aggressive analgesia, and possibly vasodilators could abort the crisis and prevent or minimize further damage. Chronic pain syndromes are associated with or accompany avascular necrosis and leg ulcers. Neuropathic pain is not well studied in patients with sickle cell disease but has been modeled in the transgenic sickle mouse. Management of sickle cell pain should be based on its own pathophysiologic mechanisms rather than borrowing guidelines from other nonsickle pain syndromes.Keywords
This publication has 95 references indexed in Scilit:
- Blockade of PDGFR-β activation eliminates morphine analgesic toleranceNature Medicine, 2012
- Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on ManagementThe Scientific World Journal, 2012
- Potential Autonomic Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control StudyThe Journal of Pain, 2011
- Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain CrisisJAMA, 2011
- Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at HomeJournal of Pain and Symptom Management, 2010
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 2009
- Pain site frequency and location in sickle cell disease: The PiSCES projectPain, 2009
- Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural PlasticityThe Journal of Pain, 2009
- Risk factors for hospital readmission within 30 days: A new quality measure for children with sickle cell diseasePediatric Blood & Cancer, 2008
- COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesiaBritish Journal of Cancer, 2007